Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this ... has announced new manufacturing projects ...

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

The new plant will be one of the largest manufacturing investments in Novo Nordisk’s history and will add 1.4 million sq ft of production space for aseptic manufacturing and finished production ...

In an indication of the challenges of meeting demand for Novo Nordisk’s weight-loss blockbuster, the company said Monday it would spend $11 billion to buy three manufacturing facilities to ramp ...

The Novo Nordisk Foundation is funding the creation of a cell therapy development and manufacturing facility ... 950 million (€127 million) in the new facility, which will be located at the ...

Novo Nordisk is scheduled to report results for ... extremely high demand for obesity drug Wegovy, with increased production capacity helping boost quarterly growth. Hansen forecasts Wegovy ...

Less than a year after Eli Lilly began selling Zepbound, sales for its obesity drug are already more than half those of Novo Nordisk’s Wegovy treatment, helping the New York-listed stock jump 54 ...